| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Droogan and Hawkins) and Immunology (Drs. Crockard and McMillan), Royal Hospitals Trust, Belfast, Northern Ireland.
Address correspondence and reprint requests to Dr. Aidan Droogan, Ward 21, Department of Neurology, Royal Hospitals Trust, Belfast BT12 6BA, Northern Ireland.
Intravenous methylprednisolone (IVMP) may inhibit inflammatory cell recruitment to active MS lesions by effects on leukocyte or endothelial cell adhesion molecule expression. We investigated 15 MS patients in relapse receiving a 5-day course of IVMP (500 mg/day) and 15 normal subjects. Patients' blood samples were obtained pretreatment, at 6 and 24 hours after the first dose, and 48 hours after completion of therapy. Levels of L-selectin, leukocyte functional antigen 1 (LFA-1), Mac-1, and very late activation antigen 4 (VLA-4) expression were determined on 
ß and
T cells and monocytes by dual-color immunofluorescent flow cytometry. Serum levels of soluble (s) L-selectin, sE-selectin, soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) were measured by ELISA. There was a marked decrease in the T-cell and monocyte counts at 6 hours after therapy, with recovery to baseline at 24 to 48 hours. Adhesion molecule expression was normal on circulating T cells and monocytes in active MS. IVMP resulted in significant changes in the percent adhesion molecule expression on monocytes: increased L-selectin expression at 24 hours, decreased Mac-1 expression at 6 hours, and decreased VLA-4 expression at 6 hours and 24 hours following treatment. T-cell adhesion molecule expression was unaffected by the therapy. Serum sE-selectin was reduced at 6 hours and 24 hours following treatment. IVMP alters the distribution and kinetics of monocyte adhesion molecule expression and endothelial cell release of E-selectin, which may limit monocyte recruitment to areas of tissue destruction in MS.
Supported by the Multiple Sclerosis Society of Great Britain and Northern Ireland.
Received March 12, 1997. Accepted in final form July 11, 1997.
This article has been cited by other articles:
|
|
 |
|
  V. Martinelli, M. A. Rocca, P. Annovazzi, A. Pulizzi, M. Rodegher, F. M. Boneschi, R. Scotti, A. Falini, M. P. Sormani, G. Comi, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS Neurology, December 1, 2009; 73(22): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ballabh, J. Kumari, A. N. Krauss, J. J. Shin, A. Jain, P. A. M. Auld, M. L. Lesser, and S. Cunningham-Rundles Soluble E-Selectin, Soluble L-Selectin and Soluble ICAM-1 in Bronchopulmonary Dysplasia, and Changes With Dexamethasone Pediatrics, March 1, 2003; 111(3): 461 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Elovaara, M. Ukkonen, M. Leppakynnas, T. Lehtimaki, M. Luomala, J. Peltola, and P. Dastidar Adhesion Molecules in Multiple Sclerosis: Relation to Subtypes of Disease and Methylprednisolone Therapy Arch Neurol, April 1, 2000; 57(4): 546 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M WHITCUP, B. P VISTICA, M T. MAGONE, and R. K GEORGE Elevated serum levels of soluble ICAM-1 in uveitis patients predict underlying systemic disease Br J Ophthalmol, February 1, 1999; 83(2): 252a - 252. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
